Heidi Anne Duerr, MPH

Expert warns lack of proper diagnosis and complete and thorough treatment of onychomycosis can lead to an endemic issue.

Designed to address the underlying causes of DEB, the investigational topical gene therapy shows great promise to improve quality of life for patients with this rare disorder.

Expert insights on the latest issues in wounds as well as HS resources are shared at the annual meeting.

Using pooled 52-week results from TRuE-AD1 and TRuE-AD2, investigators examined how the topical JAK1/JAK 2 inhibitor affects patient feelings of skin pain, discomfort, anxiety, and depression.

After reporting initial data earlier this year, investigators presented a fuller analysis in a poster at the 2022 SDPA Annual Fall Dermatology Conference.

The greatest improvements in quality of life measures were seen in the 300 mg tralokinumab group.